CO2018014167A2 - Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos - Google Patents

Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos

Info

Publication number
CO2018014167A2
CO2018014167A2 CONC2018/0014167A CO2018014167A CO2018014167A2 CO 2018014167 A2 CO2018014167 A2 CO 2018014167A2 CO 2018014167 A CO2018014167 A CO 2018014167A CO 2018014167 A2 CO2018014167 A2 CO 2018014167A2
Authority
CO
Colombia
Prior art keywords
fatty acid
butanediol
acid esters
hydroxybutyrate
methods
Prior art date
Application number
CONC2018/0014167A
Other languages
English (en)
Spanish (es)
Inventor
Eric Verdin
Scott Ulrich
John Newman
Original Assignee
Univ California
The J David Gladstone Inst
Ithaca College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, The J David Gladstone Inst, Ithaca College filed Critical Univ California
Publication of CO2018014167A2 publication Critical patent/CO2018014167A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/045—Organic compounds containing nitrogen as heteroatom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/003—Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/54—Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CONC2018/0014167A 2016-06-07 2018-12-26 Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos CO2018014167A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346975P 2016-06-07 2016-06-07
PCT/US2017/035826 WO2017213999A1 (en) 2016-06-07 2017-06-02 Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same

Publications (1)

Publication Number Publication Date
CO2018014167A2 true CO2018014167A2 (es) 2019-01-18

Family

ID=60578899

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0014167A CO2018014167A2 (es) 2016-06-07 2018-12-26 Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos

Country Status (13)

Country Link
US (4) US10889538B2 (enExample)
EP (2) EP4585270A3 (enExample)
JP (3) JP7058610B2 (enExample)
KR (2) KR102519244B1 (enExample)
CN (2) CN109477993B (enExample)
AU (2) AU2017278099B2 (enExample)
CA (1) CA3026621A1 (enExample)
CO (1) CO2018014167A2 (enExample)
IL (2) IL263561B (enExample)
MX (2) MX2021009806A (enExample)
RU (1) RU2761829C2 (enExample)
SG (1) SG11201810765PA (enExample)
WO (1) WO2017213999A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2761829C2 (ru) 2016-06-07 2021-12-13 Зе Дж. Дэвид Глэдстоун Инститьютс Образуемые среднецепочечными жирными кислотами сложные эфиры бета-гидроксибутирата и бутандиола и композиции и способы на их основе
WO2019018683A1 (en) 2017-07-21 2019-01-24 Buck Institute For Research On Aging BETA-HYDROXYBUTYRATE AND BUTANEDIOL ENANTIOMERS AND METHODS OF USE THEREOF
US12037317B2 (en) 2018-01-25 2024-07-16 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US20190248733A1 (en) * 2018-02-14 2019-08-15 Benjamin Bikman Oral supplements of fatty acid and amino acid ketone esters to improve metabolic, physical and cognitive health
WO2020147981A1 (de) * 2019-01-17 2020-07-23 Ioi Oleo Gmbh Verfahren zur herstellung von verkappten 3-hydroxycarbonsäuren sowie deren salzen und estern
EP3880642A1 (de) * 2019-01-17 2021-09-22 IOI Oleo GmbH Verfahren zur herstellung von fettalkoholestern von hydroxycarbonsäuren
CN113574048B (zh) * 2019-01-17 2024-06-18 凯托利皮克斯治疗有限责任公司 生产任选的酰化羟基羧酸的多元醇基酯的方法
CN110372502A (zh) * 2019-07-25 2019-10-25 润泰化学（泰兴）有限公司 一种1,3-二醇的双酯化合成方法
GB201918657D0 (en) 2019-12-17 2020-01-29 Tdeltas Ltd Compounds for new use
CN116113617A (zh) * 2020-07-13 2023-05-12 Ioi油脂化学品有限责任公司 氧代丁醇酯化的多元羧酸聚甘油酯的制备方法
CN116917264A (zh) * 2020-07-13 2023-10-20 凯托利皮克斯治疗有限责任公司 羟基丁酸羧酸酯的制备方法
WO2022012766A1 (de) * 2020-07-13 2022-01-20 Ioi Oleo Gmbh Verfahren zur herstellung von oxobutanol-estern von polymeren carbonsäuren
CN112341542B (zh) * 2021-01-08 2021-05-14 清华大学 一种3-羟基丁酰化修饰蛋白质药物及其制备方法和应用
BR112023014818A2 (pt) * 2021-01-26 2023-10-03 Buck Inst Res Aging Uso de ésteres de cetona exógena para induzir perda de peso em mamíferos
US12059398B2 (en) * 2022-08-26 2024-08-13 Health Via Modern Nutrition Inc. Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis
US20250009707A1 (en) 2023-06-29 2025-01-09 BOPZ Nutrition Ltd. Methods of inducing ketosis in non-human mammals

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK85610C (da) 1952-01-08 1958-05-27 Unilever Nv Fremgangsmåde til udvinding af fedstoffer af vandige sæbeopløsninger.
US4756907A (en) 1978-10-17 1988-07-12 Stolle Research & Development Corp. Active/passive immunization of the internal female reproductive organs
US4263216A (en) 1978-10-20 1981-04-21 The Procter & Gamble Company Diglyceride manufacture
IL59407A (en) * 1979-03-06 1983-12-30 Sanofi Sa Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them
US4436726A (en) 1980-12-15 1984-03-13 Fujisawa Pharmaceutical Co., Ltd. N-Acylpeptide compound, processes for the preparation thereof and the pharmaceutical compositions
BE1001209A3 (fr) 1987-11-19 1989-08-22 Solvay Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
US5126373A (en) 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
EP0556387B1 (en) 1988-04-27 1995-08-09 Daicel Chemical Industries, Ltd. Process for preparing optically active 1,3-butanediol
JP2578658B2 (ja) * 1989-02-21 1997-02-05 チッソ株式会社 光学活性化合物及びその製造法
US5008126A (en) 1989-06-27 1991-04-16 Nabisco Brands, Inc. Long chain diol diesters as low calorie fat mimetics
IT1240760B (it) * 1990-02-12 1993-12-17 Sigma Tau Ind Farmaceuti Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma.
ES2079083T3 (es) 1992-01-08 1996-01-01 Nestle Sa Composicion cosmetica o dermatologica que contiene un diol diester.
US5536249A (en) 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
DE19703471A1 (de) * 1997-01-31 1998-08-06 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Butylenglycoldiestern
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
CA2283642C (en) 1997-03-17 2012-05-15 Btg International Limited Therapeutic compositions
AU733310C (en) * 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6197327B1 (en) 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US5961495A (en) 1998-02-20 1999-10-05 Becton, Dickinson And Company Medication delivery pen having a priming mechanism
US6221053B1 (en) 1998-02-20 2001-04-24 Becton, Dickinson And Company Multi-featured medication delivery pen
US6248095B1 (en) 1998-02-23 2001-06-19 Becton, Dickinson And Company Low-cost medication delivery pen
DE60001686T2 (de) * 1999-05-11 2003-08-21 Dow Agrosciences Llc, Indianapolis Verfahren zum Herstellen von substituierten 3-Hydroxybuttersäureester
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
US6476079B1 (en) 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
US20080009467A1 (en) 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
MXPA03003022A (es) * 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de sulfuro y disulfuro y composiciones para el control del colesterol y usos relacionados.
EP1528053A1 (en) 2003-10-31 2005-05-04 Lonza Ag Process for the preparation of (S)- or (R)-4-halo-3-hydroxybutyrates
JP2006063001A (ja) 2004-08-25 2006-03-09 Takasago Internatl Corp 光学活性β−ブチロラクトンの製造方法
CN101336233A (zh) * 2005-12-07 2008-12-31 雷蒙特亚特特拉维夫大学有限公司 茉莉酮酸酯化学衍生物、其药物组合物及使用方法
US20070241306A1 (en) 2006-02-10 2007-10-18 Ann Wehner Biodegradable compositions comprising renewably-based, biodegradable 1,3-propanediol
AU2008206049A1 (en) * 2007-01-18 2008-07-24 Evolva Sa Substituted 1,3-dioxanes and their uses
JP5054418B2 (ja) * 2007-04-23 2012-10-24 ポーラ化成工業株式会社 クレンジング用の化粧料に好適な皮膚外用剤
DK2328858T3 (en) 2008-08-21 2018-01-15 Univ Oxford Innovation Ltd Drink comprehensive hydroxybutyrate ester and its medical use
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
CA2760410A1 (en) 2009-04-16 2010-10-21 Isis Innovation Limited Process for the preparation of (3r)-hydr0xybutyl (3r) -hydroxybutyrate by enzymatic enantioselective reduction employing lactobacillus brevis alcohol dehydrogenase
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
CN102858829A (zh) 2010-04-28 2013-01-02 阿科玛股份有限公司 改善含有卤化烯烃发泡剂的聚氨酯多元醇共混物的稳定性的方法
KR101243240B1 (ko) * 2010-07-19 2013-04-04 (주)에이씨티 신규 알킬디올 유도체화합물 및 이를 포함하는 미백용 피부외용제조성물
CN103360243B (zh) * 2012-03-31 2015-06-17 中国石油化工股份有限公司 一种1,3-二酰氧基丙烷类化合物的制备方法
CN104272147B (zh) 2012-05-01 2015-10-21 柯尼卡美能达株式会社 相位差膜、偏振片的制造方法及液晶显示装置
BR112015023334B1 (pt) 2013-03-14 2021-05-18 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services processo para produção de (r)-3hidroxibutil (r)-3-hidroxibutirato
CA2902603C (en) 2013-03-19 2021-03-02 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
ES2734209T3 (es) * 2013-08-06 2019-12-04 Imago Biosciences Inc Inhibidores de KDM1A para el tratamiento de enfermedades
WO2016123229A1 (en) 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders
US20180200220A1 (en) 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
RU2761829C2 (ru) 2016-06-07 2021-12-13 Зе Дж. Дэвид Глэдстоун Инститьютс Образуемые среднецепочечными жирными кислотами сложные эфиры бета-гидроксибутирата и бутандиола и композиции и способы на их основе
WO2019018683A1 (en) 2017-07-21 2019-01-24 Buck Institute For Research On Aging BETA-HYDROXYBUTYRATE AND BUTANEDIOL ENANTIOMERS AND METHODS OF USE THEREOF
US12037317B2 (en) 2018-01-25 2024-07-16 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US20190262415A1 (en) 2018-02-26 2019-08-29 Ketologie LLC Supplement for inducing and sustaining nutritional ketosis

Also Published As

Publication number Publication date
WO2017213999A1 (en) 2017-12-14
US10647658B2 (en) 2020-05-12
US11608308B2 (en) 2023-03-21
US20210171432A1 (en) 2021-06-10
US20190248730A1 (en) 2019-08-15
KR102638807B1 (ko) 2024-02-21
AU2021203726C1 (en) 2023-10-12
MX385367B (es) 2025-03-18
EP4585270A3 (en) 2025-09-24
EP4585270A2 (en) 2025-07-16
AU2021203726B2 (en) 2023-04-06
AU2021203726A1 (en) 2021-07-01
JP2024028287A (ja) 2024-03-04
BR112018075102A8 (pt) 2023-04-11
US20190382333A1 (en) 2019-12-19
RU2018143895A (ru) 2020-07-09
BR112018075102A2 (pt) 2019-03-26
MX2018015302A (es) 2019-08-22
US20190359551A1 (en) 2019-11-28
JP2019525899A (ja) 2019-09-12
IL263561A (en) 2019-01-31
KR20230006926A (ko) 2023-01-11
IL263561B (en) 2022-04-01
EP3465335A4 (en) 2020-03-11
JP7058610B2 (ja) 2022-04-22
JP7479337B2 (ja) 2024-05-08
MX2021009806A (es) 2022-11-30
KR20190026747A (ko) 2019-03-13
RU2018143895A3 (enExample) 2021-03-11
AU2017278099A1 (en) 2018-12-20
RU2761829C2 (ru) 2021-12-13
SG11201810765PA (en) 2018-12-28
AU2017278099B2 (en) 2021-03-11
NZ748897A (en) 2025-03-28
CN114292190B (zh) 2025-04-11
CA3026621A1 (en) 2017-12-14
CN109477993B (zh) 2023-03-28
US10562839B2 (en) 2020-02-18
US10889538B2 (en) 2021-01-12
KR102519244B1 (ko) 2023-04-06
JP2022020701A (ja) 2022-02-01
CN114292190A (zh) 2022-04-08
EP3465335A1 (en) 2019-04-10
NZ788931A (en) 2025-06-27
IL291694A (en) 2022-05-01
CN109477993A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
CO2018014167A2 (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos
CO2018000344A2 (es) Derivados de piperidina 1,4-sustituidos
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
DOP2017000151A (es) Derivados de quinazolina utilizados para tratar el vih
UY34888A (es) Inhibidores del virus de la hepatitis c
UY36391A (es) Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
MX2019009695A (es) Inhibidores espirociclicos de catepsina c.
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
DK3330259T3 (da) 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
DOP2018000058A (es) Inhibidores de ezh2
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
MX2017016370A (es) Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
MX2018003592A (es) Sales y formas solidas de un antibiotico de monobactam.
BR112013020975A2 (pt) compostos contendo fósforo como inibidores de proteína quinases
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
SV2018005621A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
MX2019001011A (es) Compuestos farmaceuticos.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
BR112017003745A2 (pt) inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
MX2019006920A (es) Derivados de la espiropiperidina.
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
BR112017008033A2 (pt) composição farmacêutica para administração oral e respectivo processo de preparação
BR112016017557A2 (pt) Métodos para controlar plantas daninhas usando formulações contendo herbicidas flutiacet-metila e hppd, e, composição